CO-AMP-ROBOTICS-CORP
19.7.2021 10:02:11 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, is expanding its presence in Europe as demand grows for the company’s AI and automation solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005207/en/
AMP has appointed REP-TEC Advanced Technologies , specialists in the supply, installation, and support of recycling equipment, as an official reseller and integrator for customers in the United Kingdom and Ireland. In addition, to further support the expansion of its business in Europe, AMP has hired Gary Ashburner as its European General Manager to build out the company’s infrastructure across the region. Based in the UK, Ashburner leads customer and partner acquisition, pre- and post-sales consulting, system design, supply, installation, training, and service.
“We’re seeing greater interest in and adoption of our technology in the U.S., with customers reordering our AI-guided robotic sorting systems to install in other facilities that they own. This is generating a robust pipeline in the U.S. that’s being mirrored internationally, following the installation of our first robotic sorting system in Europe late last year,” said Ashburner. “We share a commitment to improving global resource efficiency and productivity with REP-TEC, and look forward to working with an established leader that also embraces new technology and innovation as we extend our efforts to modernize and expand recycling infrastructure in Europe and globally.”
AMP’s European expansion reflects strong year-over-year revenue growth and investment in operational scale made possible by its latest funding round of USD $55 million at the beginning of the year. The company’s AI platform, AMP Neuron™, encompasses the largest known real-world dataset of recyclable materials for machine learning , with the ability to classify more than 100 different categories and characteristics of recyclables across single-stream recycling, e-scrap, and construction and demolition debris, and reaching an object recognition run rate of more than 10 billion items annually.
“We’re delighted to partner with AMP Robotics and support the company’s growth across the UK and Ireland,” said Colm Grimes, CEO of REP-TEC. “We recognize the desire to add AI and robotics to Europe’s recycling infrastructure and believe AMP has developed a system that will change the economics of this industry. We’ll be installing our first three AMP Cortex™ high-speed sorting systems later this summer. This will provide a great UK reference site with the ability to run material trials for interested parties.”
To further its market penetration, AMP is actively seeking to establish additional reseller partnerships in Belgium, The Netherlands, Luxembourg, Germany, and France.
About AMP Robotics™ Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, and high-value materials from construction and demolition debris.
About REP-TEC
REP-TEC was formed with a vision to improve global resource efficiency through automation and harnessing new waste recycling technologies. REP-TEC are specialists in the design, manufacture, installation, and support of a range of recycling solutions. The REP-TEC portfolio includes fully automatic balers, conveyor systems, compactors, and the AMP Cortex™ high-speed robotics systems. REP-TEC is passionate about innovation and exploring clients’ workstreams to uncover opportunities for significant efficiency improvements. With coverage throughout the UK and Ireland, REP-TEC provides nationwide aftersales service and support that meets the most demanding Service Level Agreements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005207/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom